Tiziana is seeking FDA clearance for a Phase 2 clinical trial testing the safety and efficacy of its foralumab nasal spray in ...
Ivor Elrifi, CEO of Tiziana Life Sciences, expressed enthusiasm about this milestone, stating, "We are excited to initiate this important clinical study with the support of the ALS Association grant.
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback